Univariate and multivariate Cox proportional
hazard analyses were used to estimate the hazard ratios of AKR1B10 expression for HCC development. The cumulative incidences of HCC development were evaluated by using Kaplan-Meier plot analysis and the log-rank test. Results: Of the 109 patients, 45 patients (41.3%) showed scarce AKR1B10 expression at 0%, similar to that observed in the normal liver tissues. However, the remaining 64 patients (58.7%) showed different degrees http://www.selleckchem.com/products/ganetespib-sta-9090.html of AKR1B10 expression in the liver, and the maximum AKR1B10 expression observed was 81%. During the median follow-up time of 4.8 years, 10 of the 109 patients developed HCC. Multivariate Cox proportional hazard analysis demonstrated that age and AKR1B10 expression were independent risk factors for HCC development. The receiver operator characteristics curve analysis determined that AKR1B10 expression of ≥ 15 %was a cutoff value for HCC development. The age-adjusted hazard ratio for AKR1B10 expression of ≥ 15 %was 12.8 with a 95 %confidence interval of 2.8-57.5 (P = 0.002). The 5-year cumulative incidences of HCC were 23.4 %and 3.1 %in patients with AKR1B10 expression ≥ 15 %and AKR1B10 expression < 15%, respectively (P < 0.001). Conclusion: AKR1B10 immu noreactivity in the liver could be a novel predictor of HCC development in HBV-infected patients. These results suggest the involvement of
AKR1B10 in the early stage of HBV-related hepatocarcinogenesis. Disclosures:
The following people have nothing to disclose: Masashi Mori, Takuya Genda, Takafumi Ichida, Ayato Murata, selleck Hironori Tsuzura, Shunsuke Sato, Yutaka Narita, Yoshio Kanemitsu, Sachiko Ishikawa, Tetsu Kikuchi, Katsuharu Hirano, Katsuyori Iijima, Ryo Wada, Sumio Watanabe Background&Aims: Reconstitution of human immune cells is warranted in liver chimeric mice to address hepatitis B virus (HBV)-specific immune responses. Recently, we generated NOG-Iap/p2m double KO mice which were NOG mice deficient in both MHC class I and II (DKO-NOG mice). In this study, we evaluated HBV-specific immune responses against HBV in human peripheral blood mononuclear cells (PBMC)-en-grafted DKO-NOG mice. Methods: We used NOG mice and DKO-NOG mice which are deficient in both MHC class I and II. Human HLA-A2+ 上海皓元 PBMC were injected into NOG and DKO-NOG mice via tail vein. We evaluated liver mononuclear cells (MNCs) isolated from these mice by flow cytometry to detect the engrafted human immune cells in mice. Next, we evaluated the production of anti-HBs antibody (anti-HBs) in sera of human PBMC-engrafted DKO-NOG mice after inoculation of hepatitis B vaccine. We also evaluated the induction of HBc-derived peptide-specific cytotoxic T lymphocytes (CTLs) by using specific HLA-A2+-binding tetramer after vaccination of HBc-derived peptide-pulsed dendritic cells (DCs) or hydrodynamic injection of HBV expressing vector.